Gemcitabine plus conventional-dose epirubicin versus gemcitabine plus cisplatin as first-line chemotherapy for stage IIIB/IV non-small cell lung carcinoma--a randomized phase II trial. [electronic resource]
Producer: 20090226Description: 334-43 p. digitalISSN:- 0169-5002
- Adenocarcinoma -- drug therapy
- Adult
- Aged
- Antigens, Neoplasm -- metabolism
- Antineoplastic Combined Chemotherapy Protocols -- therapeutic use
- Carcinoma, Large Cell -- drug therapy
- Carcinoma, Non-Small-Cell Lung -- drug therapy
- Carcinoma, Squamous Cell -- drug therapy
- Cisplatin -- administration & dosage
- DNA Topoisomerases, Type II -- metabolism
- DNA-Binding Proteins -- metabolism
- Deoxycytidine -- administration & dosage
- Endonucleases -- metabolism
- Epirubicin -- administration & dosage
- Female
- Humans
- Immunoenzyme Techniques
- Lung Neoplasms -- drug therapy
- Male
- Maximum Tolerated Dose
- Middle Aged
- Neoplasm Staging
- Prognosis
- Survival Rate
- Treatment Outcome
- Gemcitabine
No physical items for this record
Publication Type: Clinical Trial, Phase II; Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.